Géraldine Lautrette is a doctor in the Neurology department with clinical research experience in the field of ALS since 2010. Internal in Neurology since 2005, she obtained a University Diploma in exploration of clinical neurophysiology at the Pierre and Marie Curie faculty, in Paris, in 2009. Then she obtained an Inter-university diploma of “inflammatory pathologies of the Central Nervous System” in 2010 and an Inter-university diploma of “sleep and its pathology” in 2012. Today she is part-time in the service of Neurological Functional Explorations, specialized in sleep pathologies and part-time within the ALS center.
RT001 in Amyotrophic Lateral Sclerosis
In this phase 2 trial, we will study the safety and efficacy of the compound RT001 in people living with ALS. This clinical trial is sponsored by Retrotope Inc.
This phase 3 trial aims to study the safety and efficacy of the drug ‘ravulizumab’ in people living with ALS. To register for this study, you should contact your local ALS centre or treating physician.
Biogen is conducting a clinical trial to evaluate the safety and potential efficacy of an investigational drug for people with Amyotrophic Lateral Sclerosis (ALS) with a SOD1 gene mutation.
This trial will evaluate the efficacy of tauroursodeoxycholic acid (TUDCA) as add-on treatment for people with ALS.